(TOP (S (NP (DT The) (organization (NNP Food) (CC and) (NNP Drug) (NNP Administration))) (VP (VBD said) (SBAR (S (NP (organization (NNP American) (NNP Home) (NNPS Products) (NNP Corp.))) (VP (VBD agreed) (S (VP (TO to) (VP (VB recall) (NP (NP (JJ certain) (JJ generic) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (AUX were) (VP (VBN produced) (PP (IN by) (NP (NP (PRP$ its) (NNP Quantum) (NNP Pharmics) (NN unit)) (PP (IN in) (NP (NP (NNP Amityville)) (, ,) (NP (NNP N.Y)))))))))))))))))) (. .)) )
(TOP (S (NP (NNP Quantum)) (VP (VBD stopped) (VP (VBG shipping) (NP (DT the) (NNS drugs)) (NP (date (JJ last) (NN month))) (, ,) (PP (VBG following) (NP (NP (DT a) (JJ federal) (NN investigation)) (VP (VBG regarding) (NP (NP (NN information)) (SBAR (S (NP (DT the) (NN company)) (VP (VBD supplied) (S (VP (TO to) (VP (VB obtain) (NP (CD three) (NN drug) (NNS approvals)))))))))))))) (. .)) )
(TOP (S (NP (DT The) (organization (NNP FDA))) (VP (VBD requested) (NP (NP (DT the) (NN recall)) (PP (IN of) (NP (NP (NNP Quantum) (POS 's)) (NN mioxidil) (NNS tablets) (, ,) (NN chlorazepate) (NN dipotassium) (NNS tablets) (CC and) (NN meclofenamate) (NN sodium) (NNS capsules)))) (SBAR (IN because) (PRN (, ,) (S (NP (PRP it)) (VP (VBD said))) (, ,)) (S (NP (NP (DT the) (NN size)) (PP (IN of) (NP (NP (DT the) (NN production) (NNS runs)) (VP (VBN submitted) (PP (IN for) (NP (NN testing))) (S (VP (TO to) (VP (VB gain) (NP (organization (NNP FDA)) (NN approval))))))))) (VP (AUX was) (PP (IN in) (NP (DT each) (NN case))) (VP (VBD misrepresented) (PP (IN as) (ADJP (ADJP (RB much) (JJR larger)) (SBAR (IN than) (S (NP (PRP it)) (ADVP (RB actually)) (VP (AUX was))))))))))) (. .)) )
(TOP (S (NP (NP (organization (NNP American) (NNP Home) (NNP Products))) (, ,) (VP (VBN based) (PP (IN in) (NP (location (NNP New) (NNP York))))) (, ,)) (VP (VBD agreed) (S (VP (TO to) (VP (VB recall) (NP (NP (CD four) (JJ other) (NNS products)) (, ,) (NP (NN trazadone) (, ,) (NN doxepin) (, ,) (NN diazepam) (CC and) (NN lorazapam)) (, ,)) (PP (IN because) (IN of) (NP (NP (NNS concerns)) (PP (IN about) (NP (NP (NNS data)) (VP (VBN submitted) (PP (IN in) (NP (PRP$ their) (JJ original) (NN approval) (NNS applications))) (PP (IN before) (NP (DT the) (organization (NNP FDA))))))))))))) (. .)) )
(TOP (S (S (NP (NP (DT No) (NN safety) (NNS problems)) (PP (IN with) (NP (DT the) (NNS products)))) (VP (AUX are) (VP (VBN known)))) (, ,) (NP (DT the) (organization (NNP FDA))) (VP (VBD said)) (. .)) )
(TOP (S (NP (DT An) (organization (NNP FDA)) (NN spokesperson)) (VP (VBD said) (SBAR (S (NP (DT the) (NNS drugs)) (VP (AUX are) (ADVP (RB still)) (ADJP (JJ available)) (PP (IN under) (NP (JJ other) (NN brand) (NNS names))))))) (. .)) )
(TOP (S (NP (date (JJ Last) (NN month))) (, ,) (NP (organization (NNP American) (NNP Home) (NNPS Products))) (VP (VBD said) (SBAR (S (NP (PRP it)) (VP (AUX was) (VP (VBG suspending) (NP (NP (NN production) (CC and) (NN distribution)) (PP (IN of) (NP (NP (DT all) (CD 21)) (PP (IN of) (NP (NP (NNP Quantum) (POS 's)) (JJ generic) (NN drug) (NNS products)))))) (PP (VBG pending) (NP (NP (DT the) (NN completion)) (PP (IN of) (NP (DT an) (JJ exhaustive) (JJ internal) (NN audit)))))))))) (. .)) )
(TOP (S (NP (PRP It)) (ADVP (RB also)) (ADVP (RB temporarily)) (VP (VBD closed) (NP (NNP Quantum)) (, ,) (PP (IN because) (IN of) (NP (NP (DT the) (JJ internal) (NN investigation)) (, ,) (RB as) (RB well) (IN as) (NP (NP (DT the) (organization (NNP FDA)) (POS 's)) (JJ ongoing) (NN inquiry))))) (. .)) )
(TOP (S (PP (IN In) (NP (organization (NNP New) (NNP York) (NNP Stock) (NNP Exchange)) (JJ composite) (NN trading))) (, ,) (NP (organization (NNP American) (NNP Home) (NNP Products))) (VP (VBD rose) (money (NP (CD 75) (NNS cents)) (PP (TO to) (NP ($ $) (CD 105)))) (PP (IN on) (NP (date (NNP Friday))))) (. .)) )
